belantamab mafodotin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antitumor, monoclonal antibodies 5405 2050232-20-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • belantamab mafodotin
  • belantamab
  • belantamab mafodotin-blmf
  • blenrep
  • anti-BCMA-ADC
  • GSK2857914
  • GSK-2857916
  • J6M0-mcMMAF
Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 25, 2020 EMA GlaxoSmithKline (Ireland) Limited
May 8, 2020 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 756.67 73.79 89 675 379 50603981
Visual acuity reduced 422.12 73.79 89 675 20050 50584310
Night blindness 349.06 73.79 44 720 352 50604008
Dry eye 198.16 73.79 53 711 32042 50572318
Foreign body sensation in eyes 139.07 73.79 24 740 1787 50602573
Photophobia 84.02 73.79 23 741 14864 50589496

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 963.43 62.86 116 768 262 29573381
Visual acuity reduced 509.39 62.86 111 773 14765 29558878
Night blindness 434.17 62.86 54 830 167 29573476
Dry eye 217.91 62.86 49 835 7247 29566396
Photophobia 139.92 62.86 33 851 5962 29567681
Foreign body sensation in eyes 136.55 62.86 22 862 531 29573112
Punctate keratitis 101.94 62.86 16 868 324 29573319
Corneal epithelial microcysts 91.61 62.86 10 874 3 29573640

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1203.47 55.55 148 1251 632 64496701
Visual acuity reduced 678.65 55.55 148 1251 26993 64470340
Night blindness 615.25 55.55 77 1322 378 64496955
Dry eye 325.29 55.55 83 1316 28936 64468397
Foreign body sensation in eyes 232.07 55.55 39 1360 1710 64495623
Photophobia 171.52 55.55 45 1354 17248 64480085
Corneal epithelial microcysts 146.40 55.55 16 1383 13 64497320
Punctate keratitis 105.73 55.55 18 1381 847 64496486
Ocular toxicity 103.84 55.55 17 1382 629 64496704
Keratitis 65.62 55.55 15 1384 3222 64494111
Corneal disorder 61.07 55.55 13 1386 2014 64495319
Corneal cyst 58.45 55.55 6 1393 0 64497333

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX15 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
IgG receptor FcRn large subunit p51 Membrane receptor BINDING AGENT Kd 7.28 DRUG LABEL DRUG LABEL
High affinity immunoglobulin gamma Fc receptor I Membrane receptor BINDING AGENT Kd 8.15 DRUG LABEL DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A Membrane receptor BINDING AGENT Kd 7.55 DRUG LABEL DRUG LABEL
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen BINDING AGENT Kd 9 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D11595 KEGG_DRUG
DB1041CXDG UNII
C5227411 UMLSCUI
CHEMBL4298209 ChEMBL_ID
DB15719 DRUGBANK_ID
CHEMBL4298208 ChEMBL_ID
11117 IUPHAR_LIGAND_ID
2387833 RXNORM
337068 MMSL
38715 MMSL
d09613 MMSL
895362005 SNOMEDCT_US
896748005 SNOMEDCT_US
4039621 VANDF
4039622 VANDF
10797 INN_ID
018466 NDDF
C000631691 MESH_SUPPLEMENTAL_RECORD_UI
10754 INN_ID
2061894-48-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections